Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bone Neoplasms | 45 | 2023 | 2565 | 3.590 |
Why?
|
Sarcoma | 37 | 2024 | 1806 | 3.450 |
Why?
|
Osteosarcoma | 35 | 2022 | 911 | 2.730 |
Why?
|
Chordoma | 20 | 2022 | 349 | 2.460 |
Why?
|
Soft Tissue Neoplasms | 15 | 2023 | 1164 | 1.290 |
Why?
|
Drug Resistance, Multiple | 13 | 2017 | 255 | 1.210 |
Why?
|
Liposarcoma | 10 | 2024 | 289 | 1.170 |
Why?
|
Doxorubicin | 21 | 2024 | 2234 | 0.940 |
Why?
|
Sarcoma, Synovial | 7 | 2024 | 156 | 0.910 |
Why?
|
Drug Resistance, Neoplasm | 27 | 2018 | 5341 | 0.790 |
Why?
|
Ilium | 2 | 2014 | 155 | 0.770 |
Why?
|
Antineoplastic Agents | 29 | 2023 | 13676 | 0.740 |
Why?
|
Hemangioendothelioma, Epithelioid | 2 | 2024 | 54 | 0.670 |
Why?
|
RNA-Binding Protein EWS | 6 | 2024 | 211 | 0.650 |
Why?
|
Giant Cell Tumor of Bone | 5 | 2019 | 119 | 0.630 |
Why?
|
Benzofurans | 3 | 2014 | 138 | 0.630 |
Why?
|
Histone Deacetylase Inhibitors | 5 | 2021 | 778 | 0.590 |
Why?
|
Leiomyosarcoma | 6 | 2024 | 426 | 0.580 |
Why?
|
Pyrimidines | 10 | 2023 | 3048 | 0.580 |
Why?
|
Carcinoma, Giant Cell | 1 | 2016 | 5 | 0.550 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2016 | 681 | 0.540 |
Why?
|
Hydroxamic Acids | 3 | 2014 | 483 | 0.530 |
Why?
|
Sarcoma, Clear Cell | 4 | 2024 | 72 | 0.510 |
Why?
|
Extremities | 9 | 2024 | 870 | 0.510 |
Why?
|
Furans | 4 | 2024 | 199 | 0.500 |
Why?
|
RNA, Neoplasm | 5 | 2020 | 749 | 0.500 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11878 | 0.500 |
Why?
|
Gene Expression Regulation, Neoplastic | 19 | 2024 | 8647 | 0.480 |
Why?
|
Cell Line, Tumor | 50 | 2024 | 17140 | 0.480 |
Why?
|
Pyridines | 9 | 2024 | 2894 | 0.460 |
Why?
|
Liposarcoma, Myxoid | 3 | 2024 | 60 | 0.440 |
Why?
|
Spinal Neoplasms | 5 | 2022 | 715 | 0.430 |
Why?
|
Oncogene Proteins, Fusion | 6 | 2024 | 1613 | 0.420 |
Why?
|
Paclitaxel | 13 | 2017 | 1733 | 0.410 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 371 | 0.400 |
Why?
|
Gastrointestinal Stromal Tumors | 5 | 2022 | 617 | 0.400 |
Why?
|
Phthalazines | 1 | 2014 | 397 | 0.390 |
Why?
|
Chondrosarcoma | 4 | 2023 | 306 | 0.370 |
Why?
|
Cyclin-Dependent Kinases | 4 | 2017 | 663 | 0.370 |
Why?
|
Spine | 2 | 2017 | 1140 | 0.370 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 710 | 0.360 |
Why?
|
Cell Proliferation | 25 | 2020 | 10474 | 0.360 |
Why?
|
MicroRNAs | 9 | 2020 | 3803 | 0.360 |
Why?
|
Quinolines | 5 | 2016 | 772 | 0.360 |
Why?
|
Piperazines | 6 | 2024 | 2554 | 0.360 |
Why?
|
ras Proteins | 4 | 2001 | 1058 | 0.360 |
Why?
|
Combined Modality Therapy | 12 | 2024 | 8542 | 0.350 |
Why?
|
Carbolines | 2 | 2024 | 295 | 0.340 |
Why?
|
RNA, Small Interfering | 12 | 2016 | 3428 | 0.340 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1385 | 0.330 |
Why?
|
Ketones | 2 | 2024 | 183 | 0.330 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2014 | 2885 | 0.320 |
Why?
|
Hemangiosarcoma | 2 | 2024 | 215 | 0.320 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2023 | 9419 | 0.320 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2014 | 724 | 0.320 |
Why?
|
PTEN Phosphohydrolase | 1 | 2014 | 1120 | 0.310 |
Why?
|
Humans | 159 | 2024 | 768166 | 0.300 |
Why?
|
Solitary Fibrous Tumors | 2 | 2020 | 70 | 0.300 |
Why?
|
Lumbar Vertebrae | 2 | 2016 | 1885 | 0.290 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2016 | 2433 | 0.290 |
Why?
|
Sarcoma, Alveolar Soft Part | 3 | 2016 | 44 | 0.290 |
Why?
|
STAT3 Transcription Factor | 6 | 2011 | 874 | 0.290 |
Why?
|
Protein Kinase Inhibitors | 9 | 2024 | 5703 | 0.280 |
Why?
|
Apoptosis | 21 | 2017 | 9523 | 0.280 |
Why?
|
Molecular Targeted Therapy | 7 | 2021 | 2830 | 0.270 |
Why?
|
Adult | 71 | 2024 | 223646 | 0.270 |
Why?
|
Mediastinal Neoplasms | 1 | 2009 | 403 | 0.270 |
Why?
|
Neoadjuvant Therapy | 10 | 2024 | 2907 | 0.270 |
Why?
|
Middle Aged | 71 | 2024 | 223492 | 0.260 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2021 | 565 | 0.250 |
Why?
|
Ovarian Neoplasms | 8 | 2017 | 4916 | 0.250 |
Why?
|
Epigenesis, Genetic | 3 | 2020 | 3833 | 0.250 |
Why?
|
Pleural Neoplasms | 2 | 2020 | 612 | 0.240 |
Why?
|
Young Adult | 38 | 2024 | 60066 | 0.240 |
Why?
|
Piperidines | 4 | 2016 | 1667 | 0.240 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2024 | 33 | 0.230 |
Why?
|
Disease-Free Survival | 12 | 2024 | 6847 | 0.230 |
Why?
|
Aged | 55 | 2024 | 171504 | 0.230 |
Why?
|
Neoplasm Metastasis | 9 | 2024 | 4912 | 0.230 |
Why?
|
Female | 87 | 2024 | 397192 | 0.220 |
Why?
|
Population Surveillance | 1 | 2014 | 2596 | 0.220 |
Why?
|
Male | 78 | 2024 | 364719 | 0.220 |
Why?
|
Odontogenic Tumors | 1 | 2024 | 48 | 0.220 |
Why?
|
Drug Screening Assays, Antitumor | 6 | 2012 | 719 | 0.220 |
Why?
|
Kruppel-Like Transcription Factors | 2 | 2019 | 507 | 0.210 |
Why?
|
Mutation | 9 | 2022 | 30238 | 0.210 |
Why?
|
Gene Targeting | 2 | 2017 | 841 | 0.210 |
Why?
|
Prognosis | 25 | 2023 | 30010 | 0.210 |
Why?
|
Protein Methyltransferases | 2 | 2000 | 54 | 0.210 |
Why?
|
Sacrum | 4 | 2022 | 274 | 0.210 |
Why?
|
Retroperitoneal Neoplasms | 3 | 2020 | 335 | 0.210 |
Why?
|
Anilides | 2 | 2023 | 413 | 0.200 |
Why?
|
Oncogenes | 4 | 2022 | 1234 | 0.200 |
Why?
|
Cyclin D1 | 1 | 2024 | 453 | 0.200 |
Why?
|
Oleanolic Acid | 3 | 2010 | 43 | 0.200 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2016 | 622 | 0.200 |
Why?
|
Pyrimidinones | 1 | 2024 | 386 | 0.200 |
Why?
|
Fibromatosis, Aggressive | 2 | 2013 | 125 | 0.190 |
Why?
|
Lung Neoplasms | 4 | 2020 | 13586 | 0.190 |
Why?
|
Treatment Outcome | 27 | 2024 | 65371 | 0.190 |
Why?
|
Luminescent Proteins | 3 | 2001 | 838 | 0.190 |
Why?
|
Drug Synergism | 7 | 2017 | 1760 | 0.190 |
Why?
|
Hyaluronic Acid | 2 | 2015 | 484 | 0.190 |
Why?
|
Survival Analysis | 10 | 2020 | 10101 | 0.190 |
Why?
|
Fibrosarcoma | 1 | 2023 | 313 | 0.180 |
Why?
|
Chondroblastoma | 1 | 2020 | 47 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2014 | 564 | 0.180 |
Why?
|
Lymphocytes | 1 | 2008 | 2614 | 0.180 |
Why?
|
Dioxoles | 3 | 2010 | 96 | 0.180 |
Why?
|
Tetrahydroisoquinolines | 3 | 2010 | 81 | 0.180 |
Why?
|
RNA, Messenger | 6 | 2020 | 12800 | 0.180 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 905 | 0.170 |
Why?
|
Purines | 1 | 2024 | 615 | 0.170 |
Why?
|
Quantitative Trait Loci | 1 | 2008 | 2131 | 0.170 |
Why?
|
Maximum Tolerated Dose | 3 | 2024 | 899 | 0.170 |
Why?
|
Tissue Array Analysis | 7 | 2017 | 551 | 0.170 |
Why?
|
Bone Density Conservation Agents | 2 | 2019 | 797 | 0.170 |
Why?
|
Salivary Gland Neoplasms | 1 | 2024 | 306 | 0.170 |
Why?
|
Neoplasms, Second Primary | 2 | 2018 | 1061 | 0.170 |
Why?
|
Protein Prenylation | 1 | 2000 | 70 | 0.170 |
Why?
|
Aminopyridines | 1 | 2024 | 580 | 0.170 |
Why?
|
Phenylurea Compounds | 2 | 2014 | 531 | 0.170 |
Why?
|
RNA Interference | 4 | 2016 | 2832 | 0.170 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 1 | 2020 | 104 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 11 | 2019 | 6526 | 0.170 |
Why?
|
Protein Isoforms | 1 | 2024 | 1715 | 0.170 |
Why?
|
Aged, 80 and over | 21 | 2024 | 59629 | 0.160 |
Why?
|
Pleura | 1 | 2020 | 248 | 0.160 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2020 | 1791 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 819 | 0.160 |
Why?
|
RANK Ligand | 1 | 2020 | 321 | 0.160 |
Why?
|
Musculoskeletal System | 1 | 2021 | 188 | 0.160 |
Why?
|
Biopsy | 5 | 2020 | 6793 | 0.160 |
Why?
|
beta Catenin | 2 | 2014 | 1047 | 0.160 |
Why?
|
Ifosfamide | 4 | 2024 | 233 | 0.160 |
Why?
|
Lipopolysaccharides | 2 | 2024 | 2219 | 0.150 |
Why?
|
Recombinant Fusion Proteins | 4 | 2019 | 3740 | 0.150 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9615 | 0.150 |
Why?
|
rho GTP-Binding Proteins | 1 | 2000 | 279 | 0.150 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2017 | 36 | 0.150 |
Why?
|
Lymph Nodes | 1 | 2009 | 3474 | 0.150 |
Why?
|
Chromatin | 4 | 2024 | 2981 | 0.150 |
Why?
|
Adolescent | 30 | 2023 | 89169 | 0.150 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2018 | 187 | 0.150 |
Why?
|
Thoracic Wall | 1 | 2019 | 203 | 0.150 |
Why?
|
Dacarbazine | 3 | 2016 | 552 | 0.150 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7454 | 0.150 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2019 | 169 | 0.140 |
Why?
|
Golgi Apparatus | 1 | 1999 | 406 | 0.140 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2024 | 3611 | 0.140 |
Why?
|
Fatal Outcome | 2 | 2014 | 1836 | 0.140 |
Why?
|
Nanoparticles | 3 | 2015 | 1985 | 0.140 |
Why?
|
Carcinoma | 2 | 2024 | 2332 | 0.140 |
Why?
|
Cell Survival | 11 | 2017 | 5777 | 0.140 |
Why?
|
Drug Administration Schedule | 5 | 2017 | 4860 | 0.140 |
Why?
|
Chondrosarcoma, Mesenchymal | 1 | 2016 | 12 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3671 | 0.140 |
Why?
|
Child | 27 | 2023 | 80917 | 0.140 |
Why?
|
In Situ Hybridization | 1 | 2020 | 1903 | 0.140 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2017 | 286 | 0.130 |
Why?
|
SOX9 Transcription Factor | 1 | 2017 | 145 | 0.130 |
Why?
|
Gene Expression Profiling | 10 | 2020 | 9538 | 0.130 |
Why?
|
Retrospective Studies | 22 | 2022 | 81762 | 0.130 |
Why?
|
Spiro Compounds | 1 | 2016 | 69 | 0.130 |
Why?
|
Pain | 4 | 2019 | 5100 | 0.130 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2020 | 633 | 0.130 |
Why?
|
Endoplasmic Reticulum | 2 | 1999 | 1133 | 0.130 |
Why?
|
Follow-Up Studies | 16 | 2020 | 39348 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 1 | 2015 | 31 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2024 | 1179 | 0.130 |
Why?
|
Limb Salvage | 2 | 2016 | 488 | 0.130 |
Why?
|
Benzylidene Compounds | 1 | 2015 | 25 | 0.130 |
Why?
|
Protein Kinases | 2 | 2015 | 1611 | 0.130 |
Why?
|
Cell Movement | 6 | 2018 | 5210 | 0.120 |
Why?
|
Gene Regulatory Networks | 2 | 2024 | 1752 | 0.120 |
Why?
|
Antifibrinolytic Agents | 1 | 2018 | 289 | 0.120 |
Why?
|
Genomic Imprinting | 1 | 2017 | 326 | 0.120 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2019 | 542 | 0.120 |
Why?
|
Sarcoma, Experimental | 1 | 2014 | 117 | 0.120 |
Why?
|
Mice, Nude | 7 | 2016 | 3623 | 0.120 |
Why?
|
Immunity, Cellular | 1 | 2020 | 1561 | 0.120 |
Why?
|
Cryosurgery | 1 | 2019 | 479 | 0.120 |
Why?
|
Transcription Factors | 1 | 2014 | 12168 | 0.120 |
Why?
|
Indoles | 4 | 2016 | 1836 | 0.120 |
Why?
|
Bone Marrow Examination | 1 | 2014 | 154 | 0.120 |
Why?
|
Anemia | 1 | 2024 | 1514 | 0.120 |
Why?
|
Cell Cycle Proteins | 5 | 2016 | 3445 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 362 | 0.110 |
Why?
|
Neurofibromatosis 1 | 1 | 2019 | 561 | 0.110 |
Why?
|
Radiotherapy Dosage | 6 | 2018 | 2916 | 0.110 |
Why?
|
Therapeutic Equivalency | 1 | 2013 | 134 | 0.110 |
Why?
|
Genes, p53 | 1 | 2015 | 714 | 0.110 |
Why?
|
Fetal Proteins | 1 | 2013 | 100 | 0.110 |
Why?
|
Cell Membrane | 2 | 2000 | 3655 | 0.110 |
Why?
|
France | 1 | 2014 | 497 | 0.100 |
Why?
|
Retreatment | 1 | 2014 | 598 | 0.100 |
Why?
|
Fibromatosis, Abdominal | 1 | 2012 | 21 | 0.100 |
Why?
|
Fractures, Spontaneous | 1 | 2014 | 232 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2017 | 594 | 0.100 |
Why?
|
Fractures, Stress | 1 | 2015 | 205 | 0.100 |
Why?
|
Photons | 1 | 2016 | 594 | 0.100 |
Why?
|
Thiazolidinediones | 1 | 2015 | 461 | 0.100 |
Why?
|
Back Pain | 1 | 2016 | 548 | 0.100 |
Why?
|
Gene Knockdown Techniques | 5 | 2016 | 1606 | 0.100 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 1105 | 0.100 |
Why?
|
Cell Line | 4 | 2012 | 15597 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2040 | 0.100 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 631 | 0.100 |
Why?
|
Lentivirus | 3 | 2010 | 518 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 5 | 2024 | 2062 | 0.100 |
Why?
|
Pyrrolidinones | 1 | 2012 | 116 | 0.100 |
Why?
|
Receptor, IGF Type 1 | 2 | 2015 | 384 | 0.100 |
Why?
|
Histones | 3 | 2020 | 2601 | 0.090 |
Why?
|
Lysine | 1 | 2016 | 1000 | 0.090 |
Why?
|
Blotting, Western | 7 | 2015 | 5027 | 0.090 |
Why?
|
Treatment Failure | 2 | 2014 | 2661 | 0.090 |
Why?
|
Pteridines | 1 | 2011 | 47 | 0.090 |
Why?
|
Child, Preschool | 14 | 2020 | 42669 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2020 | 1890 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1338 | 0.090 |
Why?
|
T-Box Domain Proteins | 1 | 2013 | 472 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 525 | 0.090 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 627 | 0.090 |
Why?
|
Radiosurgery | 1 | 2020 | 1330 | 0.090 |
Why?
|
Immunohistochemistry | 7 | 2023 | 11095 | 0.090 |
Why?
|
Receptors, Androgen | 1 | 2017 | 1089 | 0.090 |
Why?
|
Sulfonamides | 1 | 2020 | 1982 | 0.090 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2018 | 957 | 0.090 |
Why?
|
Benzylisoquinolines | 1 | 2010 | 15 | 0.090 |
Why?
|
Survival Rate | 8 | 2019 | 12840 | 0.090 |
Why?
|
Transfection | 4 | 2016 | 5755 | 0.090 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2012 | 257 | 0.090 |
Why?
|
Carcinoma, Renal Cell | 2 | 2023 | 3187 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2020 | 3556 | 0.080 |
Why?
|
Podophyllotoxin | 1 | 2009 | 20 | 0.080 |
Why?
|
Repressor Proteins | 2 | 2019 | 2982 | 0.080 |
Why?
|
Administration, Oral | 2 | 2014 | 4030 | 0.080 |
Why?
|
Gene Expression | 6 | 2017 | 7598 | 0.080 |
Why?
|
Hoarseness | 1 | 2009 | 63 | 0.080 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4120 | 0.080 |
Why?
|
Tibia | 1 | 2015 | 1076 | 0.080 |
Why?
|
Receptors, Growth Factor | 1 | 2010 | 324 | 0.080 |
Why?
|
rho-Associated Kinases | 1 | 2011 | 290 | 0.080 |
Why?
|
Growth Inhibitors | 1 | 2010 | 375 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 13014 | 0.080 |
Why?
|
Safety | 1 | 2013 | 1159 | 0.080 |
Why?
|
Green Fluorescent Proteins | 4 | 2010 | 2065 | 0.080 |
Why?
|
Ribonucleoprotein, U4-U6 Small Nuclear | 1 | 2008 | 13 | 0.080 |
Why?
|
Autophagy | 1 | 2017 | 1349 | 0.080 |
Why?
|
Tumor Cells, Cultured | 5 | 2017 | 6124 | 0.080 |
Why?
|
Neoplasm Staging | 7 | 2024 | 11244 | 0.080 |
Why?
|
Interleukin-6 | 2 | 2010 | 3228 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 368 | 0.080 |
Why?
|
Positron-Emission Tomography | 3 | 2020 | 6669 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1560 | 0.080 |
Why?
|
Kidney Neoplasms | 2 | 2023 | 4282 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 7 | 2020 | 20760 | 0.080 |
Why?
|
Myelodysplastic Syndromes | 1 | 2018 | 1399 | 0.080 |
Why?
|
Blood Proteins | 1 | 2013 | 1191 | 0.070 |
Why?
|
Protein Processing, Post-Translational | 1 | 2016 | 1966 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 2 | 2011 | 4528 | 0.070 |
Why?
|
Hedgehog Proteins | 1 | 2012 | 771 | 0.070 |
Why?
|
Neoplasms | 2 | 2013 | 22371 | 0.070 |
Why?
|
Interleukin-17 | 1 | 2013 | 924 | 0.070 |
Why?
|
Radiology | 1 | 2021 | 2104 | 0.070 |
Why?
|
Binding Sites | 3 | 2023 | 6020 | 0.070 |
Why?
|
Th17 Cells | 1 | 2013 | 791 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1627 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2022 | 725 | 0.070 |
Why?
|
Signal Transduction | 5 | 2014 | 23645 | 0.070 |
Why?
|
Drug Approval | 1 | 2013 | 821 | 0.070 |
Why?
|
Animals | 20 | 2024 | 169246 | 0.070 |
Why?
|
Cell Division | 4 | 2017 | 4473 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9613 | 0.070 |
Why?
|
Cell Culture Techniques | 4 | 2018 | 1667 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2846 | 0.060 |
Why?
|
Nuclear Proteins | 4 | 2016 | 5804 | 0.060 |
Why?
|
Time Factors | 7 | 2019 | 40218 | 0.060 |
Why?
|
Radiography | 2 | 2014 | 6983 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2954 | 0.060 |
Why?
|
Subcellular Fractions | 2 | 2010 | 525 | 0.060 |
Why?
|
Cough | 1 | 2009 | 598 | 0.060 |
Why?
|
Fluoresceins | 3 | 2010 | 235 | 0.060 |
Why?
|
Receptors, Interleukin-6 | 1 | 2007 | 224 | 0.060 |
Why?
|
Methylation | 2 | 2016 | 1078 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2018 | 640 | 0.060 |
Why?
|
Gene Transfer Techniques | 1 | 2010 | 1207 | 0.060 |
Why?
|
Benzamides | 3 | 2017 | 1379 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2457 | 0.060 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2007 | 640 | 0.060 |
Why?
|
Necrosis | 2 | 2022 | 1616 | 0.060 |
Why?
|
Mice | 13 | 2024 | 82029 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 2 | 2013 | 3781 | 0.060 |
Why?
|
Cisplatin | 4 | 2014 | 1660 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3643 | 0.060 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2009 | 737 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2631 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2013 | 2323 | 0.060 |
Why?
|
Deoxycytidine | 2 | 2019 | 887 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2013 | 4352 | 0.060 |
Why?
|
Pyrazoles | 1 | 2014 | 2028 | 0.060 |
Why?
|
src-Family Kinases | 2 | 2018 | 539 | 0.060 |
Why?
|
WT1 Proteins | 1 | 2024 | 183 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2014 | 3514 | 0.050 |
Why?
|
HLA-A Antigens | 1 | 2024 | 223 | 0.050 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 3620 | 0.050 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2010 | 798 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2013 | 4786 | 0.050 |
Why?
|
Tumor Burden | 3 | 2015 | 1906 | 0.050 |
Why?
|
DNA, Mitochondrial | 1 | 2008 | 872 | 0.050 |
Why?
|
Herpesvirus 4, Human | 1 | 2008 | 1082 | 0.050 |
Why?
|
Radiography, Thoracic | 1 | 2009 | 1321 | 0.050 |
Why?
|
Anticoagulants | 1 | 2018 | 4852 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2018 | 4362 | 0.050 |
Why?
|
Drug Resistance | 1 | 2008 | 1599 | 0.050 |
Why?
|
Neoplasm Proteins | 4 | 2018 | 3603 | 0.050 |
Why?
|
Mesna | 2 | 2012 | 62 | 0.050 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 2232 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2013 | 3114 | 0.050 |
Why?
|
HL-60 Cells | 2 | 2000 | 364 | 0.050 |
Why?
|
Down-Regulation | 3 | 2015 | 2937 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2017 | 10760 | 0.050 |
Why?
|
Kinetics | 2 | 2020 | 6329 | 0.050 |
Why?
|
Histone Deacetylases | 2 | 2021 | 717 | 0.050 |
Why?
|
Osteoblasts | 3 | 2012 | 1145 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3626 | 0.050 |
Why?
|
Lymphatic Metastasis | 1 | 2009 | 2914 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 296 | 0.050 |
Why?
|
SEER Program | 2 | 2017 | 1444 | 0.050 |
Why?
|
DNA Primers | 2 | 2008 | 2828 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2810 | 0.050 |
Why?
|
Receptors, Cell Surface | 1 | 2010 | 2819 | 0.050 |
Why?
|
Cell Differentiation | 4 | 2023 | 11669 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 36743 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2013 | 4415 | 0.050 |
Why?
|
Protein Transport | 2 | 2020 | 1951 | 0.040 |
Why?
|
Transformation, Genetic | 1 | 2001 | 194 | 0.040 |
Why?
|
Base Sequence | 3 | 2015 | 12421 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2010 | 2056 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2892 | 0.040 |
Why?
|
RNA | 1 | 2010 | 2720 | 0.040 |
Why?
|
RNA, Viral | 1 | 2008 | 2872 | 0.040 |
Why?
|
Medical Oncology | 2 | 2022 | 2346 | 0.040 |
Why?
|
Calcium-Binding Proteins | 1 | 2024 | 1083 | 0.040 |
Why?
|
CHO Cells | 2 | 1999 | 1379 | 0.040 |
Why?
|
Leukopenia | 1 | 2019 | 212 | 0.040 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2011 | 428 | 0.040 |
Why?
|
Cricetinae | 2 | 1999 | 2423 | 0.040 |
Why?
|
Fatigue | 1 | 2006 | 1557 | 0.040 |
Why?
|
Indazoles | 1 | 2020 | 306 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 3 | 2010 | 2474 | 0.040 |
Why?
|
Infant | 5 | 2018 | 36535 | 0.040 |
Why?
|
Glucose | 1 | 2010 | 4352 | 0.040 |
Why?
|
Spheroids, Cellular | 1 | 2020 | 331 | 0.040 |
Why?
|
Protein Stability | 1 | 2020 | 580 | 0.040 |
Why?
|
Genes, ras | 1 | 2001 | 663 | 0.040 |
Why?
|
Cloning, Molecular | 2 | 2001 | 4168 | 0.040 |
Why?
|
Leukemia, Monocytic, Acute | 1 | 2017 | 58 | 0.040 |
Why?
|
RNA Stability | 1 | 2020 | 319 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2016 | 2359 | 0.040 |
Why?
|
Phosphorylation | 3 | 2017 | 8317 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2023 | 15832 | 0.040 |
Why?
|
Succinate Dehydrogenase | 1 | 2018 | 148 | 0.040 |
Why?
|
Caspases | 2 | 2011 | 882 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 8054 | 0.040 |
Why?
|
COS Cells | 1 | 1999 | 1135 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 7876 | 0.040 |
Why?
|
Utah | 1 | 2017 | 130 | 0.040 |
Why?
|
Phosphoramide Mustards | 1 | 2016 | 18 | 0.030 |
Why?
|
Phenotype | 2 | 2020 | 16726 | 0.030 |
Why?
|
Pyrroles | 2 | 2014 | 1124 | 0.030 |
Why?
|
Protons | 1 | 2022 | 1113 | 0.030 |
Why?
|
Thrombopoietin | 1 | 2018 | 225 | 0.030 |
Why?
|
Clone Cells | 1 | 2020 | 1670 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2009 | 4937 | 0.030 |
Why?
|
Isomerism | 1 | 2016 | 198 | 0.030 |
Why?
|
Methotrexate | 2 | 2013 | 1721 | 0.030 |
Why?
|
Kidney | 2 | 2023 | 7064 | 0.030 |
Why?
|
Receptors, Somatomedin | 1 | 2015 | 57 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2021 | 998 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2017 | 330 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2016 | 411 | 0.030 |
Why?
|
Adenosine Triphosphatases | 2 | 2010 | 842 | 0.030 |
Why?
|
Drug Substitution | 1 | 2018 | 291 | 0.030 |
Why?
|
DNA Methylation | 2 | 2022 | 4428 | 0.030 |
Why?
|
Inhibitory Concentration 50 | 1 | 2016 | 464 | 0.030 |
Why?
|
Receptors, Fc | 1 | 2018 | 537 | 0.030 |
Why?
|
Trans-Activators | 1 | 2024 | 2857 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2017 | 354 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 379 | 0.030 |
Why?
|
bcl-2-Associated X Protein | 1 | 2015 | 281 | 0.030 |
Why?
|
Organoids | 1 | 2020 | 743 | 0.030 |
Why?
|
Polyethyleneimine | 1 | 2014 | 68 | 0.030 |
Why?
|
Neutropenia | 1 | 2019 | 892 | 0.030 |
Why?
|
Multiprotein Complexes | 1 | 2020 | 1110 | 0.030 |
Why?
|
Dogs | 1 | 1999 | 3845 | 0.030 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2014 | 54 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2017 | 806 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2017 | 753 | 0.030 |
Why?
|
Pain Measurement | 2 | 2019 | 3583 | 0.030 |
Why?
|
Chemokine CCL3 | 1 | 2013 | 85 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 2016 | 1377 | 0.030 |
Why?
|
Transplantation, Heterologous | 2 | 2012 | 2393 | 0.030 |
Why?
|
Multiple Sclerosis | 1 | 2009 | 3250 | 0.030 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2016 | 423 | 0.030 |
Why?
|
Genetic Variation | 1 | 2008 | 6611 | 0.030 |
Why?
|
Databases, Factual | 3 | 2018 | 8080 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9263 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2021 | 1997 | 0.030 |
Why?
|
Peptide Library | 1 | 2014 | 351 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 515 | 0.030 |
Why?
|
Rhabdomyosarcoma | 1 | 2015 | 358 | 0.030 |
Why?
|
Software | 1 | 2007 | 4478 | 0.030 |
Why?
|
International Agencies | 1 | 2013 | 244 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2014 | 476 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2000 | 2414 | 0.020 |
Why?
|
Placebos | 1 | 2016 | 1667 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4580 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1703 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2016 | 614 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2923 | 0.020 |
Why?
|
Osteoclasts | 1 | 2016 | 713 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12543 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1744 | 0.020 |
Why?
|
Sex Factors | 2 | 2017 | 10632 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2015 | 683 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2001 | 6082 | 0.020 |
Why?
|
Sex Distribution | 1 | 2016 | 2278 | 0.020 |
Why?
|
Lipoma | 1 | 2013 | 296 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2018 | 1126 | 0.020 |
Why?
|
Stereoisomerism | 1 | 2012 | 612 | 0.020 |
Why?
|
G2 Phase | 1 | 2011 | 134 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2018 | 2633 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3948 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 1999 | 13421 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 590 | 0.020 |
Why?
|
Caspase 7 | 1 | 2010 | 51 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2011 | 381 | 0.020 |
Why?
|
Genomics | 2 | 2022 | 5926 | 0.020 |
Why?
|
Antirheumatic Agents | 2 | 2013 | 1381 | 0.020 |
Why?
|
Up-Regulation | 2 | 2010 | 4146 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 162 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 892 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2016 | 942 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2000 | 6514 | 0.020 |
Why?
|
Xanthenes | 1 | 2009 | 71 | 0.020 |
Why?
|
Chromosome Mapping | 2 | 2009 | 4620 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2013 | 1340 | 0.020 |
Why?
|
Rad51 Recombinase | 1 | 2010 | 191 | 0.020 |
Why?
|
Verapamil | 1 | 2010 | 242 | 0.020 |
Why?
|
Vimentin | 1 | 2010 | 257 | 0.020 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2010 | 200 | 0.020 |
Why?
|
Intracellular Space | 1 | 2010 | 199 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2540 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3628 | 0.020 |
Why?
|
Cohort Studies | 3 | 2020 | 41754 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1196 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2010 | 513 | 0.020 |
Why?
|
Age Factors | 2 | 2017 | 18412 | 0.020 |
Why?
|
Gene Silencing | 1 | 2015 | 1505 | 0.020 |
Why?
|
Keratins | 1 | 2010 | 499 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 646 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2010 | 432 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2013 | 1864 | 0.020 |
Why?
|
bcl-X Protein | 1 | 2010 | 412 | 0.020 |
Why?
|
Protein Binding | 1 | 2020 | 9343 | 0.020 |
Why?
|
Sequence Analysis | 1 | 2009 | 240 | 0.020 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2008 | 105 | 0.020 |
Why?
|
Dextrans | 1 | 2010 | 574 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2012 | 2014 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7214 | 0.020 |
Why?
|
Organ Culture Techniques | 1 | 2010 | 794 | 0.020 |
Why?
|
Caspase 3 | 1 | 2010 | 730 | 0.020 |
Why?
|
Radiotherapy | 1 | 2014 | 1502 | 0.020 |
Why?
|
Cell Hypoxia | 1 | 2010 | 662 | 0.020 |
Why?
|
Radiotherapy, Conformal | 1 | 2011 | 549 | 0.020 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 1679 | 0.020 |
Why?
|
World Health Organization | 1 | 2014 | 1329 | 0.020 |
Why?
|
Models, Chemical | 1 | 2009 | 611 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 54926 | 0.020 |
Why?
|
Acetylation | 1 | 2010 | 1056 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2012 | 1951 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2017 | 26379 | 0.020 |
Why?
|
Disease Progression | 2 | 2015 | 13671 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2009 | 577 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6231 | 0.020 |
Why?
|
Prevalence | 2 | 2015 | 15869 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6340 | 0.020 |
Why?
|
Neutrophils | 1 | 2000 | 3786 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2885 | 0.020 |
Why?
|
Mice, SCID | 1 | 2012 | 2627 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2012 | 1230 | 0.020 |
Why?
|
Blotting, Northern | 1 | 2008 | 1550 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2012 | 3055 | 0.020 |
Why?
|
Lod Score | 1 | 2007 | 600 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2665 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2744 | 0.020 |
Why?
|
Microvessels | 1 | 2010 | 585 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2016 | 18349 | 0.020 |
Why?
|
Mitosis | 1 | 2011 | 1178 | 0.020 |
Why?
|
Phenols | 1 | 2010 | 526 | 0.020 |
Why?
|
Genotype | 2 | 2013 | 13045 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2010 | 1751 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2008 | 567 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2016 | 8128 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1074 | 0.010 |
Why?
|
DNA Damage | 1 | 2014 | 2469 | 0.010 |
Why?
|
Cell Death | 1 | 2010 | 1679 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2011 | 2732 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9374 | 0.010 |
Why?
|
Research Design | 1 | 2019 | 6211 | 0.010 |
Why?
|
United States | 3 | 2016 | 73039 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3837 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1406 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7608 | 0.010 |
Why?
|
Remission Induction | 1 | 2009 | 2410 | 0.010 |
Why?
|
Cell Cycle | 1 | 2011 | 2932 | 0.010 |
Why?
|
Massachusetts | 1 | 2016 | 8890 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2014 | 9561 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2009 | 1854 | 0.010 |
Why?
|
Collagen | 1 | 2010 | 2643 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2009 | 1625 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3800 | 0.010 |
Why?
|
DNA Repair | 1 | 2009 | 2050 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4978 | 0.010 |
Why?
|
Gene Frequency | 1 | 2007 | 3623 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15454 | 0.010 |
Why?
|
Incidence | 1 | 2017 | 21538 | 0.010 |
Why?
|
Lipids | 1 | 2010 | 3343 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9495 | 0.010 |
Why?
|
Cytokines | 1 | 2013 | 7453 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2018 | 26422 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 19015 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11928 | 0.010 |
Why?
|
Alleles | 1 | 2009 | 6894 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24315 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1998 | 2748 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2010 | 20227 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 22291 | 0.010 |
Why?
|
Risk Factors | 1 | 2017 | 74944 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2006 | 15948 | 0.000 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 16045 | 0.000 |
Why?
|
Saccharomyces cerevisiae | 1 | 1998 | 2682 | 0.000 |
Why?
|
Depression | 1 | 2006 | 8230 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1998 | 17622 | 0.000 |
Why?
|